Abstract
A decade on, the effect of bone-modifying agents on breast cancer–related events remains unsettled. Practice guidelines (e.g., by the National
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
